Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1993 Dec 15;296(Pt 3):639–648. doi: 10.1042/bj2960639

Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate.

G Mascellani 1, L Liverani 1, P Bianchini 1, B Parma 1, G Torri 1, A Bisio 1, M Guerrini 1, B Casu 1
PMCID: PMC1137745  PMID: 8280062

Abstract

Dermatan sulphate (DS) obtained from bovine and pig mucosa and pig skin, and charge-enriched fractions of a selected DS preparation, were characterized in terms of charge density, M(r) and disaccharide composition of chondroitin ABC lyase digests, and by 13C-n.m.r. spectroscopy. Besides the major IdoA-GalNAc4SO3 sequences, all DS preparations contain about 10% disulphated disaccharide sequences (mostly IdoA2SO3-GalNAc4SO3, with minor amounts of IdoA-GalNAc4,6SO3). DS fragments (prepared by radical-catalysed depolymerization of DS and retaining the internal structure of the parent polysaccharide) as well as Smith degraded fragments [SD-DS, obtained by controlled degradation of periodate-oxidized and borohydride-reduced DS (RO-DS)] with the general structure GalNAc4SO3(IdoA2SO3-GalNAc4SO3)n-R (where R is the remnant of a glycol-split uronic acid, and n = 2-3 and 3-4) were characterized by one- and two-dimensional 1H-n.m.r., 13C-n.m.r. and disaccharide composition analysis. In accordance with previous findings [Maimone and Tollefsen (1990) J. Biol. Chem. 265, 18263-18271], only fragments with n > or = 3 significantly enhance the heparin cofactor II-mediated inhibition of thrombin. In natural DS preparations and their fractions, this activity (as well as the antithrombotic activity in an animal model) appears to require IdoA2SO3-containing sequences. The heparin cofactor II activity of DS, RO-DS and SD-DS fragments decreases with decreasing M(r). However, RO-DS fragments are more active than DS fragments of similar M(r), probably because of the extra flexibility endowed by glycol-split IdoA residues.

Full text

PDF
639

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abildgaard U., Larsen M. L. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma. Thromb Res. 1984 Aug 1;35(3):257–266. doi: 10.1016/0049-3848(84)90357-8. [DOI] [PubMed] [Google Scholar]
  2. Bossennec V., Petitou M., Perly B. 1H-n.m.r. investigation of naturally occurring and chemically oversulphated dermatan sulphates. Identification of minor monosaccharide residues. Biochem J. 1990 May 1;267(3):625–630. doi: 10.1042/bj2670625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Casu B., Petitou M., Provasoli M., Sinaÿ P. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci. 1988 Jun;13(6):221–225. doi: 10.1016/0968-0004(88)90088-6. [DOI] [PubMed] [Google Scholar]
  4. Dupouy D., Sié P., Dol F., Boneu B. A simple method to measure dermatan sulfate at sub-microgram concentrations in plasma. Thromb Haemost. 1988 Oct 31;60(2):236–239. [PubMed] [Google Scholar]
  5. Fransson L. A., Carlstedt I. Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers. Carbohydr Res. 1974 Sep;36(2):349–358. doi: 10.1016/s0008-6215(00)83056-6. [DOI] [PubMed] [Google Scholar]
  6. Fransson L. A. Periodate oxidation of L-iduronic acid residues in dermatan sulphate. Carbohydr Res. 1974 Sep;36(2):339–348. doi: 10.1016/s0008-6215(00)83055-4. [DOI] [PubMed] [Google Scholar]
  7. Heinegård D., Sommarin Y. Proteoglycans: an overview. Methods Enzymol. 1987;144:305–319. doi: 10.1016/0076-6879(87)44185-2. [DOI] [PubMed] [Google Scholar]
  8. Holme K. R., Perlin A. S. Nuclear magnetic resonance spectra of heparin in admixture with dermatan sulfate and other glycosaminoglycans. 2-D spectra of the chondroitin sulfates. Carbohydr Res. 1989 Mar 15;186(2):301–312. doi: 10.1016/0008-6215(89)84044-3. [DOI] [PubMed] [Google Scholar]
  9. Kinsella M. G., Wight T. N. Isolation and characterization of dermatan sulfate proteoglycans synthesized by cultured bovine aortic endothelial cells. J Biol Chem. 1988 Dec 15;263(35):19222–19231. [PubMed] [Google Scholar]
  10. Lindahl U., Hök M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem. 1978;47:385–417. doi: 10.1146/annurev.bi.47.070178.002125. [DOI] [PubMed] [Google Scholar]
  11. Linhardt R. J., al-Hakim A., Liu J. A., Hoppensteadt D., Mascellani G., Bianchini P., Fareed J. Structural features of dermatan sulfates and their relationship to anticoagulant and antithrombotic activities. Biochem Pharmacol. 1991 Sep 27;42(8):1609–1619. doi: 10.1016/0006-2952(91)90431-4. [DOI] [PubMed] [Google Scholar]
  12. Maimone M. M., Tollefsen D. M. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem. 1990 Oct 25;265(30):18263–18271. [PubMed] [Google Scholar]
  13. Mascellani G., Rasconi A., Brugnoli E., Bianchini P. Potenziometria applicata alla caratterizzazione ed analisi di polisaccaridi di uso farmaceutico. Farmaco Prat. 1988 May;43(5):165–175. [PubMed] [Google Scholar]
  14. Munakata H., Hsu C. C., Kodama C., Aikawa J., Sakurada M., Ototani N., Isemura M., Yosizawa Z., Hayashi N. Isolation of dermatan sulfate with high heparin cofactor II-mediated thrombin-inhibitory activity from porcine spleen. Biochim Biophys Acta. 1987 Sep 11;925(3):325–331. doi: 10.1016/0304-4165(87)90198-x. [DOI] [PubMed] [Google Scholar]
  15. Nimmo I. A., Bauermeister A. A least-squares method for fitting the Hill equatio to data from several animals. Anal Biochem. 1977 Oct;82(2):468–472. doi: 10.1016/0003-2697(77)90185-3. [DOI] [PubMed] [Google Scholar]
  16. Ofosu F. A., Buchanan M. R., Anvari N., Smith L. M., Blajchman M. A. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate. Ann N Y Acad Sci. 1989;556:123–131. doi: 10.1111/j.1749-6632.1989.tb22496.x. [DOI] [PubMed] [Google Scholar]
  17. Población C. A., Michelacci Y. M. Structural differences of dermatan sulfates from different origins. Carbohydr Res. 1986 Mar 1;147(1):87–100. doi: 10.1016/0008-6215(86)85009-1. [DOI] [PubMed] [Google Scholar]
  18. Pratt C. W., Whinna H. C., Meade J. B., Treanor R. E., Church F. C. Physicochemical aspects of heparin cofactor II. Ann N Y Acad Sci. 1989;556:104–115. doi: 10.1111/j.1749-6632.1989.tb22494.x. [DOI] [PubMed] [Google Scholar]
  19. Reyers I., Mussoni L., Donati M. B., de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res. 1980 Jun 1;18(5):669–674. doi: 10.1016/0049-3848(80)90221-2. [DOI] [PubMed] [Google Scholar]
  20. Sanderson P. N., Huckerby T. N., Nieduszynski I. A. Chondroitinase ABC digestion of dermatan sulphate. N.m.r. spectroscopic characterization of the oligo- and poly-saccharides. Biochem J. 1989 Jan 15;257(2):347–354. doi: 10.1042/bj2570347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scully M. F., Ellis V., Seno N., Kakkar V. V. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II. Biochem J. 1988 Sep 1;254(2):547–551. doi: 10.1042/bj2540547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sie P., Dupouy D., Caranobe C., Petitou M., Boneu B. Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II. Blood. 1993 Apr 1;81(7):1771–1777. [PubMed] [Google Scholar]
  23. Sie P., Ofosu F., Fernandez F., Buchanan M. R., Petitou M., Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol. 1986 Dec;64(4):707–714. doi: 10.1111/j.1365-2141.1986.tb02232.x. [DOI] [PubMed] [Google Scholar]
  24. Sié P., Petitou M., Lormeau J. C., Dupouy D., Boneu B., Choay J. Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II. Biochim Biophys Acta. 1988 Aug 11;966(2):188–195. doi: 10.1016/0304-4165(88)90111-0. [DOI] [PubMed] [Google Scholar]
  25. Tollefsen D. M., Pestka C. A., Monafo W. J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983 Jun 10;258(11):6713–6716. [PubMed] [Google Scholar]
  26. Tollefsen D. M. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide. Adv Exp Med Biol. 1992;313:167–176. doi: 10.1007/978-1-4899-2444-5_17. [DOI] [PubMed] [Google Scholar]
  27. Van Ryn-McKenna J., Ofosu F. A., Gray E., Hirsh J., Buchanan M. R. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann N Y Acad Sci. 1989;556:304–312. doi: 10.1111/j.1749-6632.1989.tb22512.x. [DOI] [PubMed] [Google Scholar]
  28. Yoshida K., Miyauchi S., Kikuchi H., Tawada A., Tokuyasu K. Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. Anal Biochem. 1989 Mar;177(2):327–332. doi: 10.1016/0003-2697(89)90061-4. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES